New antibody drug targets advanced cancers in Mid-Stage trial

NCT ID NCT07290088

Recruiting now Disease control Sponsor: Intra-IMMUSG Pte Ltd Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 20 times

Summary

This study tests a new drug, PRL3-zumab, in 52 adults with advanced solid tumors that have not responded well to prior treatments. The drug is given every two weeks by IV. The main goal is to see how long the cancer stays under control and whether the drug is safe. This is not a cure, but aims to slow disease progression.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beacon Hospital
RECRUITING

Kuala Lumpur, Malaysia

Contact Email: •••••@•••••
Hosp. Kuala Lumpur
RECRUITING

Kuala Lumpur, Malaysia

Contact Email: •••••@•••••
Hosp. Universiti Sains Malaysia (HUSM), Kelantan
RECRUITING

Kota Bharu, Malaysia

Contact Email: •••••@•••••
University Malaysia Medical Centre
RECRUITING

Kuala Lumpur, Malaysia

Contact Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID CANCERS